Druggable targets and therapeutic development for COVID-19. [PDF]
Front Chem, 2022 Duan X, Lacko LA, Chen S.
europepmc +1 more source
Coronavirus Infection 2019 (COVID-19) and Autoimmunity. [PDF]
Her Russ Acad Sci, 2022 Nasonov EL, Samsonov MY, Lila AM.
europepmc +1 more source
COVID-19: A Comprehensive Review on Cardiovascular Alterations, Immunity, and Therapeutics in Older Adults. [PDF]
J Clin Med, 2023 Rivera-Torres J, Girón N, San José E.
europepmc +1 more source
Immune-Based Therapy for Hospitalized Patients With COVID-19 and Risk of Secondary Infections: A Systematic Review and Meta-analysis. [PDF]
Open Forum Infect Dis, 2023 Kabbani D +11 more
europepmc +1 more source
Research on Liver Damage Caused by the Treatment of Rheumatoid Arthritis with Novel Biological Agents or Targeted Agents. [PDF]
J Inflamm Res, 2023 Zhao X +7 more
europepmc +1 more source
Integrating multi-modal omics to identify therapeutic atherosclerosis pathways for coronary heart disease. [PDF]
EBioMedicinede Ruiter SC +9 more
europepmc +2 more sources
The role of monoclonal antibodies against IL-6 or IL-6R in the treatment of thyroid eye disease. [PDF]
Rev Endocr Metab DisordEzra DG +7 more
europepmc +1 more source
Recent updates in the clinical trials of therapeutic monoclonal antibodies targeting cytokine storm for the management of COVID-19. [PDF]
Heliyon, 2021 Patel S, Saxena B, Mehta P.
europepmc +1 more source
Rarely listed essential medicines in 158 national lists. [PDF]
J Pharm Policy PractUl Haq MZ +4 more
europepmc +1 more source
Targeting IL-6 or IL-6 Receptor in Rheumatoid Arthritis: What Have We Learned? [PDF]
BioDrugsAvci AB, Feist E, Burmester GR.
europepmc +1 more source